Teva Aims To Revoke Rival's Blood Transfusion Drug Patent

Law360, London (April 8, 2021, 3:26 PM BST) -- Generic drugs manufacturer Teva has taken Novartis AG to court in a bid to invalidate two of the pharmaceutical giant's patents for a blood transfusion medicine, arguing that the its rival's claimed intellectual property did not involve an "inventive step."

The High Court claim by the Israeli company and its British subsidiary maintains that the two patents for Novartis' iron-reducing drug Exjade suggest medical advances that would have been obvious to a skilled person working in that field of life-science because of other inventions and common general knowledge.

The claims of each of the patents involve nothing more than an "arbitrary...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!